Fairvalue-Calculator Fairvalue-Calculator
EN DE

Verrica Pharmaceuticals Inc (VRCA) Fair Value & Analysis

Healthcare · US · Market cap $100M

Price$5.85
Fair Value$6.48
Upside+10.8%
Quality95/100
Evidence: Low Range $4.86 – $8.10

Fair value as of: Jun 25, 2026

Analysis

Verrica Pharmaceuticals Inc (VRCA) currently trades at $5.85, while our model-based Fair Value estimate is $6.48 — implying the stock looks roughly 10.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-m…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Verrica Pharmaceuticals Inc (VRCA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $6.48 versus a price of $5.85 — about +11% (undervalued). Model-based estimate, not financial advice.
What is the fair value of VRCA?
Our 21-model fair value for Verrica Pharmaceuticals Inc is $6.48 (as of Jun 25, 2026), built from audited fundamentals. The current price is $5.85.
What is the quality score of VRCA?
Verrica Pharmaceuticals Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.